Theravance Biopharma TBPH Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 1.2%+78.1pp | -3.4%+69.6pp | -40.9%+28.8pp | -48.2%+19.4pp | -76.9%-8.1pp | |
| Net margin | 104.3%+194pp | 98.5%+186pp | 36.5%+115pp | 16.9%+90.5pp | -89.4%-16.6pp | |
| EBITDA margin | 2.7%+77.0pp | -1.8%+68.4pp | -38.8%+28.2pp | -46%+18.9pp | -74.3%-8.4pp | |
| Returns | ||||||
| Return on equity | 50.2%+81.6pp | 44.8%+73.9pp | 14%+36.9pp | 6.2%+25.5pp | -31.5%— | |
| Return on assets | 28.1%+44.4pp | 25.2%+40.5pp | 7.6%+20.4pp | 3.3%+14.6pp | -16.3%-6.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.1× | 0.3×+0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 13.1×+8.4× | 10.9×+5.9× | 9.5×+4.5× | 6.7×+1.5× | 4.8×-1.0× | |
| Quick ratio | 13.1×+8.4× | 10.9×+5.9× | 9.5×+4.5× | 6.7×+1.5× | 4.8×-1.0× | |
| Cash ratio | 9.1×+5.6× | 4.4×+3.2× | 4.7×+3.7× | 5.2×+3.1× | 3.5×+1.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.2× | 0.1×-0.1× | 0.2×-0.1× | 0.2×0.0× | 0.3×+0.1× | |
| Debt-to-assets | 0.1×-0.1× | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $5.67+69.7% | $5.76+60.3% | $4.48+18.4% | $4.43+11.6% | $3.34-21.3% | |
| Valuation | ||||||
| Market capitalization | $890.32M+68.7% | $948.08M+105% | $735.27M+87.1% | $533.51M+30.3% | $441.77M-0.3% | |
| Enterprise value | $642.72M+38.3% | $822.98M+73.3% | $605.1M+46.0% | $298.04M-27.3% | $379.31M-13.3% | |
| Price / earnings | 7.8×— | —— | —— | —— | —— | |
| Price / sales | 8.1×0.0× | 8.8×+1.6× | 9.2×+2.9× | 6.9×+0.3× | 6.8×-0.4× | |
| Price / book | 3.1×-0.1× | 3.2×+0.6× | 3.2×+1.0× | 2.4×+0.3× | 2.7×+0.5× | |
| EV / sales | 5.9×-1.3× | 7.7×+0.3× | 7.5×+1.0× | 3.9×-2.7× | 5.8×-1.3× | |
| Earnings yield | 12.8%+23.8pp | 11.2%+23.4pp | 4%+16.6pp | 2.4%+13.6pp | -13.2%-3.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Theravance Biopharma's profit margins?
- Theravance Biopharma (TBPH) runs a 60.8% gross margin and a 1.2% operating margin, with a 104.3% net margin.
- Where do Theravance Biopharma's ratios come from?
- Every ratio is computed from Theravance Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
